

PATENT

10/01/01
09/966724
PTO
Jc997 U.S.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of) Prior Group Art Unit: 1632
)
KINZLER *et al.*) Prior Examiner: S. Priebe
)
Continuation of)
Serial No. 08/390,474)
)
Filed: October 1, 2001) Atty. Dkt. No. 01107.00193

For: **AMPLIFICATION OF MDM2 GENE OF HUMAN MDM2 GENE IN
HUMAN TUMORS**

INFORMATION DISCLOSURE STATEMENT


Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Pursuant to the duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a) Applicant submits herewith a Form PTO 1449. Since these documents were previously cited in Application Serial No. 08/390,474 no copies are being supplied herewith.

Applicant respectfully requests that the Examiner consider and enter these documents into the file of the above-identified application. No fee is believed to be due to ensure consideration and entry of the cited documents by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,


Sarah A. Kagan
Registration No. 32,141

Dated: October 1, 2001

BANNER & WITCOFF, LTD.
1001 G Street, N.W., 11th Floor
Washington, D.C. 20001
TEL: (202) 508-9100
FAX: (202) 508-9299

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	TBA/Continuation of 08/390,474
Filing Date	September 28, 2001
First Named Inventor	KINZLER et al.
Prior Group Art Unit	1632
Prior Examiner Name	S. Priebe
Attorney Docket Number	01107.00193

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BW/		Fakharzadeh, et al., "Tumorigenic Potential Associated with Enhanced Expression of a Gene That is Amplified in a Mouse Tumor Cell Line", <i>The EMBO Journal</i> , 10(6):1565-1569 (1991)	
/BW/		Hinds, et al., "Mutant p53 DNA Clones From Human Colon Carcinomas Cooperate with Ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes", <i>Cell Growth & Differentiation</i> , 1:561-580 (1990)	
		Romkes, et al., "Cloning and Expression of cDNA for Multiple Members of the Human Cytochrome P450/C Subfamily", <i>Biochemistry</i> , 30(13):3247-3255 (1991)	
/BW/		Momand, et al., "The MDM2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation", <i>Cell</i> , 69:1237-1245 (1992)	
		Oliner, et al., "Amplification of a Gene Encoding a p53-Associated Protein in Human Sarcomas", <i>Nature</i>, 358:80-83 (1992)	
/BW/		Ladanyi, et al., "MDM2 Gene Amplification in Metastatic Osteosarcoma", <i>Cancer Research</i> , 53:2231-2234 (1993)	
/BW/		Oliner, et al., "Oncoprotein MDM2 Conceals the Activation Domain of Tumour Suppressor p53", <i>Nature</i> , 362(6423):857-860 (1993)	
/BW/		Cahilly, et al., "Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line", <i>Somatic Cell and Molecular Genetics</i> , 13(3):235-244 (1987)	
/BW/		Hodgson, <i>Exp. Opin. Ther. Pat.</i> , 5(5), 1995, 459-468	
		Uhlmann et al., <i>Stem. Rev.</i>, 9(44), 1998, 544-564	
		Cubier et al., <i>TIG</i>, 10(5), 1994, 174-178	
/BW/		Leach, et al., "p53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas", <i>Cancer Research</i> , 53:2231-2234 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	TBA/Continuation of 08/390,474
Filing Date	September 28, 2001
First Named Inventor	KINZLER et al.
Group Art Unit	1632
Examiner Name	S. Priebe
Attorney Docket Number	01107.00193

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ‡
/BW/		Narayanan et al., <u>Oncogene</u> , 1992, 7(3), 553-561	
/BW/		Levine et al., <u>Nature</u> , 351, 1991, 453-456	
		Marshall, <u>Science</u>, 269, 1995, 1050-1055	
/BW/		Stein et al., <u>Science</u> , 261, 1993, 1004-1012	
/BW/		Wu-Pong, <u>Pharm. Tech.</u> , 18, 1994, 102-114	
		Miller et al., <u>FASEB</u>, 9, 1995, 190-199	
		Rojanasakul, <u>Adv. Drug Del. Rev.</u>, 18 (1996), 115-131	
/BW/		Miller, <u>J. Med. Chem.</u> , 36(14):1423-1437, 1993	
		Milligan	

Examiner Signature	/Brian Whiteman/	Date Considered	04/10/2008
--------------------	------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.